Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non-Current Debt for 7 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 24.7% to $48.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 million, a 24.7% increase, with the full-year FY2025 number at $48.2 million, up 24.7% from a year prior.
  • Non-Current Debt was $48.2 million for Q4 2025 at Akebia Therapeutics, up from $47.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $97.2 million in Q3 2021 to a low of $17.2 million in Q4 2023.
  • A 5-year average of $47.3 million and a median of $38.5 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: tumbled 49.58% in 2023, then surged 125.18% in 2024.
  • Akebia Therapeutics' Non-Current Debt stood at $97.2 million in 2021, then plummeted by 64.95% to $34.1 million in 2022, then crashed by 49.58% to $17.2 million in 2023, then surged by 125.18% to $38.7 million in 2024, then rose by 24.7% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Debt are $48.2 million (Q4 2025), $47.6 million (Q3 2025), and $47.1 million (Q2 2025).